Xconomy’s Digital Events →
Akero’s FGF21 analog yields 63 percent to 72 percent relative hepatic fat reduction in Phase 2a study; the company awaits biopsy data hoping to see a fibrotic benefit. Also, Genfit says... Read more »
Sponsored · Video
A Fireside Chat with Biocom President & CEO Joe Panetta
Sponsored · Whitepaper
A Guide to Performing Check-ups on Pharmaceutical Distribution & Patient Access Programs
A Fireside Chat with Medpace's Regulatory Affairs Director David Horton
© 2007-2021, Xconomy, Inc.
Xconomy is a registered service mark of Xconomy, Inc.
All rights reserved.